Clinical evaluation of CyberKnife in the treatment of vestibular schwannomas

Jo-Ting Tsai, Jia-Wei Lin, Chien-Min Lin, Yuan Hao Chen, Hsin I. Ma, Yee Min Jen, Yi Hsun Chen, D. T. Ju

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective. This study assessed the posttreatment tumor control and auditory function of vestibular schwannoma (VS) patients after CyberKnife (CK) and analyzed the possible prognostic factors of hearing loss. Methods. We retrospectively studied 117 VS patients, with Gardner-Robertson (GR) classification grades I to IV, who underwent CK between 2006 and 2012. Data including radiosurgery treatment parameters, pre- and postoperative tumor size, and auditory function were collected and examined. Results. With CK, 117 patients had excellent tumor control rates (99.1%), with a mean imaging followup of 61.1 months. Excluding 52 patients (GR III-IV pretreatment), 53 (81.5%) of the remaining 65 patients (initial GR I-II) maintained GR I or II hearing after CK, with a mean audiometric followup of 64.5 months. Twelve patients experienced hearing degradation (91.6% were GR II pretreatment); they appeared to have significantly larger tumor sizes, significantly smaller cochlear sizes, and higher prescribed cochlear doses, compared to the patients with preserved hearing. Conclusion. Our data showed that CK treatment provided an excellent tumor control rate and a comparable hearing preservation rate in VS patients. Patients with pretreatment GR II hearing levels, larger tumor volumes, smaller cochlear sizes, and higher prescribed cochlear doses may have poor hearing prognoses.

Original languageEnglish
Article number297093
JournalBioMed Research International
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Acoustic Neuroma
Audition
Tumors
Hearing
Cochlea
Therapeutics
Neoplasms
Radiosurgery
Tumor Burden
Hearing Loss
Imaging techniques
Degradation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Clinical evaluation of CyberKnife in the treatment of vestibular schwannomas. / Tsai, Jo-Ting; Lin, Jia-Wei; Lin, Chien-Min; Chen, Yuan Hao; Ma, Hsin I.; Jen, Yee Min; Chen, Yi Hsun; Ju, D. T.

In: BioMed Research International, Vol. 2013, 297093, 2013.

Research output: Contribution to journalArticle

Tsai, Jo-Ting ; Lin, Jia-Wei ; Lin, Chien-Min ; Chen, Yuan Hao ; Ma, Hsin I. ; Jen, Yee Min ; Chen, Yi Hsun ; Ju, D. T. / Clinical evaluation of CyberKnife in the treatment of vestibular schwannomas. In: BioMed Research International. 2013 ; Vol. 2013.
@article{7c6f15bba7f541e6a175220f6eee2a6e,
title = "Clinical evaluation of CyberKnife in the treatment of vestibular schwannomas",
abstract = "Objective. This study assessed the posttreatment tumor control and auditory function of vestibular schwannoma (VS) patients after CyberKnife (CK) and analyzed the possible prognostic factors of hearing loss. Methods. We retrospectively studied 117 VS patients, with Gardner-Robertson (GR) classification grades I to IV, who underwent CK between 2006 and 2012. Data including radiosurgery treatment parameters, pre- and postoperative tumor size, and auditory function were collected and examined. Results. With CK, 117 patients had excellent tumor control rates (99.1{\%}), with a mean imaging followup of 61.1 months. Excluding 52 patients (GR III-IV pretreatment), 53 (81.5{\%}) of the remaining 65 patients (initial GR I-II) maintained GR I or II hearing after CK, with a mean audiometric followup of 64.5 months. Twelve patients experienced hearing degradation (91.6{\%} were GR II pretreatment); they appeared to have significantly larger tumor sizes, significantly smaller cochlear sizes, and higher prescribed cochlear doses, compared to the patients with preserved hearing. Conclusion. Our data showed that CK treatment provided an excellent tumor control rate and a comparable hearing preservation rate in VS patients. Patients with pretreatment GR II hearing levels, larger tumor volumes, smaller cochlear sizes, and higher prescribed cochlear doses may have poor hearing prognoses.",
author = "Jo-Ting Tsai and Jia-Wei Lin and Chien-Min Lin and Chen, {Yuan Hao} and Ma, {Hsin I.} and Jen, {Yee Min} and Chen, {Yi Hsun} and Ju, {D. T.}",
year = "2013",
doi = "10.1155/2013/297093",
language = "English",
volume = "2013",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Clinical evaluation of CyberKnife in the treatment of vestibular schwannomas

AU - Tsai, Jo-Ting

AU - Lin, Jia-Wei

AU - Lin, Chien-Min

AU - Chen, Yuan Hao

AU - Ma, Hsin I.

AU - Jen, Yee Min

AU - Chen, Yi Hsun

AU - Ju, D. T.

PY - 2013

Y1 - 2013

N2 - Objective. This study assessed the posttreatment tumor control and auditory function of vestibular schwannoma (VS) patients after CyberKnife (CK) and analyzed the possible prognostic factors of hearing loss. Methods. We retrospectively studied 117 VS patients, with Gardner-Robertson (GR) classification grades I to IV, who underwent CK between 2006 and 2012. Data including radiosurgery treatment parameters, pre- and postoperative tumor size, and auditory function were collected and examined. Results. With CK, 117 patients had excellent tumor control rates (99.1%), with a mean imaging followup of 61.1 months. Excluding 52 patients (GR III-IV pretreatment), 53 (81.5%) of the remaining 65 patients (initial GR I-II) maintained GR I or II hearing after CK, with a mean audiometric followup of 64.5 months. Twelve patients experienced hearing degradation (91.6% were GR II pretreatment); they appeared to have significantly larger tumor sizes, significantly smaller cochlear sizes, and higher prescribed cochlear doses, compared to the patients with preserved hearing. Conclusion. Our data showed that CK treatment provided an excellent tumor control rate and a comparable hearing preservation rate in VS patients. Patients with pretreatment GR II hearing levels, larger tumor volumes, smaller cochlear sizes, and higher prescribed cochlear doses may have poor hearing prognoses.

AB - Objective. This study assessed the posttreatment tumor control and auditory function of vestibular schwannoma (VS) patients after CyberKnife (CK) and analyzed the possible prognostic factors of hearing loss. Methods. We retrospectively studied 117 VS patients, with Gardner-Robertson (GR) classification grades I to IV, who underwent CK between 2006 and 2012. Data including radiosurgery treatment parameters, pre- and postoperative tumor size, and auditory function were collected and examined. Results. With CK, 117 patients had excellent tumor control rates (99.1%), with a mean imaging followup of 61.1 months. Excluding 52 patients (GR III-IV pretreatment), 53 (81.5%) of the remaining 65 patients (initial GR I-II) maintained GR I or II hearing after CK, with a mean audiometric followup of 64.5 months. Twelve patients experienced hearing degradation (91.6% were GR II pretreatment); they appeared to have significantly larger tumor sizes, significantly smaller cochlear sizes, and higher prescribed cochlear doses, compared to the patients with preserved hearing. Conclusion. Our data showed that CK treatment provided an excellent tumor control rate and a comparable hearing preservation rate in VS patients. Patients with pretreatment GR II hearing levels, larger tumor volumes, smaller cochlear sizes, and higher prescribed cochlear doses may have poor hearing prognoses.

UR - http://www.scopus.com/inward/record.url?scp=84890064123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890064123&partnerID=8YFLogxK

U2 - 10.1155/2013/297093

DO - 10.1155/2013/297093

M3 - Article

VL - 2013

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 297093

ER -